Briefing: India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Strategic angle: Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
Browse the full archive, newest first.
Strategic angle: Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
Major infrastructure project aims to revitalize former uranium site in Ohio.
Strategic angle: A detailed analysis of the technology behind Windows Start menu.
Strategic angle: A new Caltech study reveals a link between drought conditions and the increase of antibiotic-resistant microorganisms in soils, potentially impacting public health.